Food and drug administration gives breakthrough: sanctioning of Rezdiffra for non-alcoholic steatohepatitis
DOI:
https://doi.org/10.18203/2349-3933.ijam20243826Keywords:
US food and drug administration, Rezdiffra, Noncirrhotic non-alcoholic steatohepatitisAbstract
On March 14,2024, FDA i.e., the US food and drug administration, approved Rezdiffra (resmetirom) for treating noncirrhotic non-alcoholic steatohepatitis (NASH) in adults who may have moderate to advanced degrees of liver fibrosis. This is a game-changing moment for patients who until now had only diet and exercise as their options.
Metrics
References
Commissioner office. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA. Available at: https://www.fda.gov/newsevents/pressannouncements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed on 25 March 2024.
Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Internal Med. 2022;292(2):190-204.
Resmetirom. Go.drugbank.com. Available at: https://go.drugbank.com/drugs/DB12914. Accessed on 25 March 2024.
Madrigal Pharmaceuticals Announces FDA Approval of RezdiffraTM (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis | Madrigal Pharmaceuticals. Available at: Ir.madrigalpharma.com. Accessed on 25 March 2024.
Watson AR. Rezdiffra (resmetirom). Medicalnewstoday.com; Medical News Today. Available at: https://www.medicalnewstoday.com/articles/drugs-rezdiffra#side-effects. Accessed on 10 June 2024.
Downloads
Published
How to Cite
Issue
Section
